Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Phase 1 Recruiting
30 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
Phase 1 Recruiting
30 enrolled
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 Recruiting
60 enrolled
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 Recruiting
98 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 Recruiting
42 enrolled
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
12 enrolled
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Phase 1 Recruiting
340 enrolled
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Phase 1 Recruiting
165 enrolled
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Phase 1 Recruiting
20 enrolled
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Phase 1 Recruiting
154 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
18 enrolled
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 Recruiting
120 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 Recruiting
60 enrolled
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 Recruiting
140 enrolled
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Phase 1 Recruiting
15 enrolled
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 Recruiting
148 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Phase 1 Recruiting
27 enrolled
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Phase 1 Recruiting
15 enrolled
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
38 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled
ASHA-1
Phase 1 Recruiting
40 enrolled